Recently, unimolecular, multifunctional peptides combining GLP-1Ra with GIP has been considered as a promising therapeutic agent for insight against T2DM, suggested that these two incretins can act on β-cells through distinct metabolic effects synergistically and complementarily [31]. The gene discussed is GIP; the disease is type 2 diabetes mellitus.